{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:50:44Z","timestamp":1792086644210,"version":"4.4.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"DOI":"10.1007\/s11427-025-3268-1","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:12:58Z","timestamp":1792041178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating cell-free Epstein-Barr virus DNA measurement for nasopharyngeal carcinoma: advancing towards ctDNA-guided, risk-adaptive individualized treatment"],"prefix":"10.1007","author":[{"given":"Kun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"3268_CR1","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1128\/JVI.74.3.1224-1233.2000","volume":"74","author":"AL Adamson","year":"2000","unstructured":"Adamson, A.L., Darr, D., Holley-Guthrie, E., Johnson, R.A., Mauser, A., Swenson, J., and Kenney, S. (2000). Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 74, 1224\u20131233.","journal-title":"J Virol"},{"key":"3268_CR2","doi-asserted-by":"publisher","first-page":"115625","DOI":"10.1016\/j.ejca.2025.115625","volume":"226","author":"S Alfieri","year":"2025","unstructured":"Alfieri, S., Roman\u00f2, R., Marceglia, S., Sciortino, C., Ferrari Bravo, W., Zucchini, M., Piscitelli, M.L., Nuzzolese, I., Cavalieri, S., Bergamini, C., et al. (2025). Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study. Eur J Cancer 226, 115625.","journal-title":"Eur J Cancer"},{"key":"3268_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMe1706815","volume":"377","author":"RF Ambinder","year":"2017","unstructured":"Ambinder, R.F. (2017). Plasma Epstein-Barr virus DNA for screening. N Engl J Med 377, 584\u2013585.","journal-title":"N Engl J Med"},{"key":"3268_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00262-022-03254-w","volume":"72","author":"M An","year":"2023","unstructured":"An, M., Wang, W., Zhang, J., Till, B.G., Zhao, L., Huang, H., Yang, Y., Li, T., Han, L., Zhang, X., et al. (2023). Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunol Immunother 72, 385\u2013395.","journal-title":"Cancer Immunol Immunother"},{"key":"3268_CR5","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1002\/cncr.25932","volume":"117","author":"X An","year":"2011","unstructured":"An, X., Wang, F., Ding, P., Deng, L., Jiang, W., Zhang, L., Shao, J., and Li, Y. (2011). Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic\/ recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117, 3750\u20133757.","journal-title":"Cancer"},{"key":"3268_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi, P., Chan, A.T., Licitra, L., Trama, A., Orlandi, E., Hui, E.P., Hal\u00e1mkov\u00e1, J., Mattheis, S., Baujat, B., Hardillo, J., et al. (2021). Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32, 452\u2013465.","journal-title":"Ann Oncol"},{"key":"3268_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/carcin\/bgz203","volume":"41","author":"J Cai","year":"2020","unstructured":"Cai, J., Chen, S., Yi, M., Tan, Y., Peng, Q., Ban, Y., Yang, J., Li, X., Zeng, Z., Xiong, W., et al. (2020). \u0394Np63\u03b1 is a super enhancer-enriched master factor controlling the basal-to-luminal differentiation transcriptional program and gene regulatory networks in nasopharyngeal carcinoma. Carcinogenesis 41, 1282\u20131293.","journal-title":"Carcinogenesis"},{"key":"3268_CR8","doi-asserted-by":"publisher","first-page":"e19100","DOI":"10.1371\/journal.pone.0019100","volume":"6","author":"SM Cao","year":"2011","unstructured":"Cao, S.M., Liu, Z., Jia, W.H., Huang, Q.H., Liu, Q., Guo, X., Huang, T.B., Ye, W., and Hong, M.H. (2011). Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One 6, e19100.","journal-title":"PLoS One"},{"key":"3268_CR9","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","volume":"94","author":"ATC Chan","year":"2002","unstructured":"Chan, A.T.C., Lo, Y.M., Zee, B., Chan, L.Y., Ma, B.B., Leung, S.F., Mo, F., Lai, M., Ho, S., Huang, D.P., et al. (2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94, 1614\u20131619.","journal-title":"J Natl Cancer Inst"},{"key":"3268_CR10","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","volume":"36","author":"ATC Chan","year":"2018","unstructured":"Chan, A.T.C., Hui, E.P., Ngan, R.K.C., Tung, S.Y., Cheng, A.C.K., Ng, W.T., Lee, V.H.F., Ma, B.B.Y., Cheng, H.C., Wong, F.C.S., et al. (2018). Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 36, 3091\u20133100.","journal-title":"J Clin Oncol"},{"key":"3268_CR11","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1373\/clinchem.2005.054783","volume":"51","author":"KA Chan","year":"2005","unstructured":"Chan, K.A., Chan, A.T., Leung, S.F., Pang, J.C., Wang, A.Y., Tong, J.H., To, K.F., Chan, L.Y., Tam, L.L., Chung, N.Y., et al. (2005). Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 51, 2192\u20132195.","journal-title":"Clin Chem"},{"key":"3268_CR12","first-page":"2028","volume":"63","author":"KC Chan","year":"2003","unstructured":"Chan, K.C., Zhang, J., Chan, A.T., Lei, K.I., Leung, S.F., Chan, L.Y., Chow, K.C., and Lo, Y.M. (2003). Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63, 2028\u20132032.","journal-title":"Cancer Res"},{"key":"3268_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2200309","DOI":"10.1056\/EVIDoa2200309","volume":"2","author":"KCA Chan","year":"2023","unstructured":"Chan, K.C.A., Lam, W.K.J., King, A., Lin, V.S., Lee, P.P.H., Zee, B.C.Y., Chan, S.L., Tse, I.O.L., Tsang, A.F.C., Li, M.Z.J., et al. (2023). Plasma Epstein-Barr virus DNA and risk of future nasopharyngeal cancer. NEJM Evid 2, EVIDoa2200309.","journal-title":"NEJM Evid"},{"key":"3268_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan, K.C.A., Woo, J.K.S., King, A., Zee, B.C.Y., Lam, W.K.J., Chan, S.L., Chu, S.W.I., Mak, C., Tse, I.O.L., Leung, S.Y.M., et al. (2017). Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377, 513\u2013522.","journal-title":"N Engl J Med"},{"key":"3268_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3389\/fonc.2020.01417","volume":"10","author":"SK Chan","year":"2020","unstructured":"Chan, S.K., Chan, S.Y., Choi, H.C.W., Tong, C.C., Lam, K.O., Kwong, D.L.W., Vardhanabhuti, V., Leung, T.W., Luk, M.Y., Lee, A.W.M., et al. (2020). Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy. Front Oncol 10, 1417.","journal-title":"Front Oncol"},{"key":"3268_CR16","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.32770","volume":"126","author":"F Chen","year":"2020","unstructured":"Chen, F., Huang, X., Lv, J., Wen, D., Zhou, G., Lin, L., Kou, J., Wu, C., Chen, Y., Zheng, Z., et al. (2020). Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer 126, 2163\u20132173.","journal-title":"Cancer"},{"key":"3268_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40880-016-0089-z","volume":"35","author":"JL Chen","year":"2016","unstructured":"Chen, J.L., Lin, X.J., Zhou, Q., Shi, M., Li, S.P., and Lao, X.M. (2016). Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. Chin J Cancer 35, 28.","journal-title":"Chin J Cancer"},{"key":"3268_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y.P., Chan, A.T.C., Le, Q.T., Blanchard, P., Sun, Y., and Ma, J. (2019). Nasopharyngeal carcinoma. Lancet 394, 64\u201380.","journal-title":"Lancet"},{"key":"3268_CR19","first-page":"194","volume":"66","author":"MC Chia","year":"2006","unstructured":"Chia, M.C., Leung, A., Krushel, T., Alajez, N., Bastianutto, C., and Liu, F.F. (2006). Radiation and cisplatin activation of EBV in nasopharyngeal cancer: understanding the oncolytic potential of EBV. Cancer Research 66, 194\u2013194.","journal-title":"Cancer Research"},{"key":"3268_CR20","doi-asserted-by":"publisher","first-page":"8583","DOI":"10.18632\/oncotarget.2323","volume":"5","author":"SH Chiu","year":"2014","unstructured":"Chiu, S.H., Wu, C.C., Fang, C.Y., Yu, S.L., Hsu, H.Y., Chow, Y.H., and Chen, J.Y. (2014). Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma. Oncotarget 5, 8583\u20138601.","journal-title":"Oncotarget"},{"key":"3268_CR21","doi-asserted-by":"publisher","first-page":"1501139","DOI":"10.3389\/fmicb.2025.1501139","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui, H., Li, S., Lv, W., and Xiang, J. (2025). Association of hepatitis B virus DNA levels with efficacy and safety and the impact of antiviral therapy on prognosis in liver cancer patients receiving immune checkpoint inhibitors therapy: a systematic review and meta-analysis. Front Microbiol 16, 1501139.","journal-title":"Front Microbiol"},{"key":"3268_CR22","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1128\/JVI.79.6.3409-3418.2005","volume":"79","author":"T Daikoku","year":"2005","unstructured":"Daikoku, T., Kudoh, A., Fujita, M., Sugaya, Y., Isomura, H., Shirata, N., and Tsurumi, T. (2005). Architecture of replication compartments formed during Epstein-Barr virus lytic replication. J Virol 79, 3409\u20133418.","journal-title":"J Virol"},{"key":"3268_CR23","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S.C., and Raab-Traub, N. (2022). Epstein-Barr virus: biology and clinical disease. Cell 185, 3652\u20133670.","journal-title":"Cell"},{"key":"3268_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.11604\/pamj.2022.41.6.28946","volume":"41","author":"I EL Alami","year":"2022","unstructured":"EL Alami, I., Gihbid, A., Charoute, H., Khaali, W., Brahim, S.M., Tawfiq, N., Cadi, R., Belghmi, K., El Mzibri, M., and Khyatti, M. (2022). Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis. Pan Afr Med J 41, 6.","journal-title":"Pan Afr Med J"},{"key":"3268_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/ijc.20520","volume":"112","author":"H Fan","year":"2004","unstructured":"Fan, H., Nicholls, J., Chua, D., Chan, K.H., Sham, J., Lee, S., and Gulley, M.L. (2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Intl J Cancer 112, 1036\u20131041.","journal-title":"Intl J Cancer"},{"key":"3268_CR26","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s11427-024-2642-8","volume":"67","author":"Z Fan","year":"2024","unstructured":"Fan, Z., Hao, J., He, F., Jiang, H., Wang, J., Li, M., Li, X., Chen, R., and Wei, W. (2024). Novel DNA methylation markers for early detection of gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Sci China Life Sci 67, 2701\u20132712.","journal-title":"Sci China Life Sci"},{"key":"3268_CR27","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1002\/ijc.24179","volume":"124","author":"C Fang","year":"2009","unstructured":"Fang, C., Lee, C., Wu, C., Chang, Y., Yu, S., Chou, S., Huang, P., Chen, C., Hou, J., Chang, Y., et al. (2009). Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Intl J Cancer 124, 2016\u20132025.","journal-title":"Intl J Cancer"},{"key":"3268_CR28","first-page":"1920","volume":"62","author":"WH Feng","year":"2002","unstructured":"Feng, W.H., Israel, B., Raab-Traub, N., Busson, P., and Kenney, S.C. (2002). Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62, 1920\u20131926.","journal-title":"Cancer Res"},{"key":"3268_CR29","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.1158\/0008-5472.CAN-06-1006","volume":"66","author":"W Feng","year":"2006","unstructured":"Feng, W., and Kenney, S.C. (2006). Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66, 8762\u20138769.","journal-title":"Cancer Res"},{"key":"3268_CR30","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1128\/jvi.69.5.2998-3006.1995","volume":"69","author":"ED Fixman","year":"1995","unstructured":"Fixman, E.D., Hayward, G.S., and Hayward, S.D. (1995). Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol 69, 2998\u20133006.","journal-title":"J Virol"},{"key":"3268_CR31","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.4161\/cc.3.10.1155","volume":"3","author":"A Fomenkov","year":"2004","unstructured":"Fomenkov, A., Zangen, R., Huang, Y.P., Osada, M., Guo, Z., Fomenkov, T., Trink, B., Sidransky, D., and Ratovitski, E.A. (2004). RACK1 and stratifin target \u0394Np63\u03b1 for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 3, 1285\u20131295.","journal-title":"Cell Cycle"},{"key":"3268_CR32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3389\/fonc.2020.00600","volume":"10","author":"PM Hau","year":"2020","unstructured":"Hau, P.M., Lung, H.L., Wu, M., Tsang, C.M., Wong, K.L., Mak, N.K., and Lo, K.W. (2020). Targeting Epstein-Barr virus in nasopharyngeal carcinoma. Front Oncol 10, 600.","journal-title":"Front Oncol"},{"key":"3268_CR33","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1084\/jem.20070256","volume":"204","author":"AD Hislop","year":"2007","unstructured":"Hislop, A.D., Ressing, M.E., van Leeuwen, D., Pudney, V.A., Horst, D., Koppers-Lalic, D., Croft, N.P., Neefjes, J.J., Rickinson, A.B., and Wiertz, E.J.H.J. (2007). A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204, 1863\u20131873.","journal-title":"J Exp Med"},{"key":"3268_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.20129","volume":"100","author":"R Hong","year":"2004","unstructured":"Hong, R., Lin, C., Ting, L., Ko, J., and Hsu, M. (2004). Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA. Cancer 100, 1429\u20131437.","journal-title":"Cancer"},{"key":"3268_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s44178-024-00140-6","volume":"3","author":"Y Hou","year":"2024","unstructured":"Hou, Y., Yang, X., and Meng, H. (2024). Pathological mechanisms and advances in neoadjuvant PD-1 blockade combined with chemotherapy for head and neck cancer. Holist Integ Oncol 3, 63.","journal-title":"Holist Integ Oncol"},{"key":"3268_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/hed.21890","volume":"34","author":"C Hsu","year":"2012","unstructured":"Hsu, C., Chang, K., Lin, C., Chang, H., Wang, C., Lin, T., Liao, C., Tsang, N., Lee, L., Chan, S., et al. (2012). Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck 34, 1064\u20131070.","journal-title":"Head Neck"},{"key":"3268_CR37","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/ijc.30816","volume":"141","author":"J Hu","year":"2017","unstructured":"Hu, J., Li, H., Luo, X., Li, Y., Bode, A., and Cao, Y. (2017). The role of oxidative stress in EBV lytic reactivation, radioresistance and the potential preventive and therapeutic implications. Intl J Cancer 141, 1722\u20131729.","journal-title":"Intl J Cancer"},{"key":"3268_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.cbi.2010.09.020","volume":"188","author":"SY Huang","year":"2010","unstructured":"Huang, S.Y., Fang, C.Y., Tsai, C.H., Chang, Y., Takada, K., Hsu, T.Y., and Chen, J.Y. (2010). N-methyl-N\u2032-nitro-N-nitrosoguanidine induces and cooperates with 12-O-tetradecanoylphorbol-1,3-acetate\/sodium butyrate to enhance Epstein-Barr virus reactivation and genome instability in nasopharyngeal carcinoma cells. Chem-Biol Interact 188, 623\u2013634.","journal-title":"Chem-Biol Interact"},{"key":"3268_CR39","doi-asserted-by":"publisher","first-page":"e84919","DOI":"10.1371\/journal.pone.0084919","volume":"8","author":"SY Huang","year":"2013","unstructured":"Huang, S.Y., Fang, C.Y., Wu, C.C., Tsai, C.H., Lin, S.F., and Chen, J.Y. (2013). Reactive oxygen species mediate Epstein-Barr virus reactivation by N-methyl-N\u2032 -nitro-N-nitrosoguanidine. PLoS One 8, e84919.","journal-title":"PLoS One"},{"key":"3268_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijrobp.2025.03.076","volume":"123","author":"Z Huang","year":"2025","unstructured":"Huang, Z., Li, Y., Wu, W., Wu, L., Chen, Z., Xu, S., Li, Y., Lai, J., Qiu, S., and Lu, J. (2025). Plasma Epstein-Barr virus DNA temporal clearance pattern during induction-concurrent (Chemo)radiation therapy for risk stratification in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 123, 129\u2013140.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3268_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcv.2006.06.013","volume":"37","author":"JH Jiang","year":"2006","unstructured":"Jiang, J.H., Wang, N., Li, A., Liao, W.T., Pan, Z.G., Mai, S.J., Li, D.J., Zeng, M.S., Wen, J., and Zeng, Y.X. (2006). Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J Clin Virol 37, 98\u2013103.","journal-title":"J Clin Virol"},{"key":"3268_CR42","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1073\/pnas.0911948107","volume":"107","author":"M Kalla","year":"2010","unstructured":"Kalla, M., Schmeinck, A., Bergbauer, M., Pich, D., and Hammerschmidt, W. (2010). AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci USA 107, 850\u2013855.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3268_CR43","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1158\/1538-7445.AM2012-2760","volume":"72","author":"H Kim","year":"2012","unstructured":"Kim, H., Lee, H.G., Park, J.H., and Lee, J.M. (2012). Abstract 2760: gemcitabine induced lytic EBV replication and confers ganciclovir susceptibility to EBV-positive gastric cancer. Cancer Res 72, 2760.","journal-title":"Cancer Res"},{"key":"3268_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/path.5249","volume":"247","author":"WKJ Lam","year":"2019","unstructured":"Lam, W.K.J., Chan, K.C.A., and Lo, Y.M.D. (2019a). Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol 247, 641\u2013649.","journal-title":"J Pathol"},{"key":"3268_CR45","doi-asserted-by":"publisher","first-page":"E5115","DOI":"10.1073\/pnas.1804184115","volume":"115","author":"WKJ Lam","year":"2018","unstructured":"Lam, W.K.J., Jiang, P., Chan, K.C.A., Cheng, S.H., Zhang, H., Peng, W., Tse, O.Y.O., Tong, Y.K., Gai, W., Zee, B.C.Y., et al. (2018). Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci USA 115, E5115\u2013E5124.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3268_CR46","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41467-019-11226-5","volume":"10","author":"WKJ Lam","year":"2019","unstructured":"Lam, W.K.J., Jiang, P., Chan, K.C.A., Peng, W., Shang, H., Heung, M.M.S., Cheng, S. H., Zhang, H., Tse, O.Y.O., Raghupathy, R., et al. (2019b). Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nat Commun 10, 3256.","journal-title":"Nat Commun"},{"key":"3268_CR47","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2025.02.002","volume":"43","author":"WKJ Lam","year":"2025","unstructured":"Lam, W.K.J., Kang, G., Chan, C.M.L., Lee, V.C.T., Ma, M.J.L., Zhou, Q., Jiang, P., Tse, I. O.L., King, A.D., Wong, K.C.W., et al. (2025). Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma. Cancer Cell 43, 728\u2013739.e5.","journal-title":"Cancer Cell"},{"key":"3268_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12011-009-8555-y","volume":"137","author":"S Lassoued","year":"2010","unstructured":"Lassoued, S., Gargouri, B., El Feki, A.F., Attia, H., and Van Pelt, J. (2010). Transcription of the Epstein-Barr virus lytic cycle activator BZLF-1 during oxidative stress induction. Biol Trace Elem Res 137, 13\u201322.","journal-title":"Biol Trace Elem Res"},{"key":"3268_CR49","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le, Q.T., Zhang, Q., Cao, H., Cheng, A.J., Pinsky, B.A., Hong, R.L., Chang, J.T., Wang, C.W., Tsao, K.C., Lo, Y.D., et al. (2013). An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 19, 2208\u20132215.","journal-title":"Clin Cancer Res"},{"key":"3268_CR50","doi-asserted-by":"publisher","first-page":"31018","DOI":"10.18632\/oncotarget.5041","volume":"6","author":"HG Lee","year":"2015","unstructured":"Lee, H.G., Kim, H., Kim, E.J., Park, P.G., Dong, S.M., Choi, T.H., Kim, H., Chong, C.R., Liu, J.O., Chen, J., et al. (2015). Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. Oncotarget 6, 31018\u201331029.","journal-title":"Oncotarget"},{"key":"3268_CR51","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S1470-2045(22)00505-8","volume":"23","author":"VHF Lee","year":"2022","unstructured":"Lee, V.H.F., Adham, M., Ben Kridis, W., Bossi, P., Chen, M.Y., Chitapanarux, I., Gregoire, V., Hao, S.P., Ho, C., Ho, G.F., et al. (2022). International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. Lancet Oncol 23, e544\u2013e551.","journal-title":"Lancet Oncol"},{"key":"3268_CR52","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/cncr.11496","volume":"98","author":"S Leung","year":"2003","unstructured":"Leung, S., Chan, A.T.C., Zee, B., Ma, B., Chan, L.Y.S., Johnson, P.J., and Dennis Lo, Y. M. (2003). Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98, 288\u2013291.","journal-title":"Cancer"},{"key":"3268_CR53","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/cas.13634","volume":"109","author":"H Li","year":"2018","unstructured":"Li, H., Hu, J., Luo, X., Bode, A.M., Dong, Z., and Cao, Y. (2018). Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. Cancer Sci 109, 2101\u20132108.","journal-title":"Cancer Sci"},{"key":"3268_CR54","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.7150\/ijbs.16564","volume":"12","author":"H Li","year":"2016","unstructured":"Li, H., Liu, S., Hu, J., Luo, X., Li, N., M.Bode, A., and Cao, Y. (2016). Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci 12, 1309\u20131318.","journal-title":"Int J Biol Sci"},{"key":"3268_CR55","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa2301496","volume":"389","author":"T Li","year":"2023","unstructured":"Li, T., Li, F., Guo, X., Hong, C., Yu, X., Wu, B., Lian, S., Song, L., Tang, J., Wen, S., et al. (2023). Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer. N Engl J Med 389, 808\u2013819.","journal-title":"N Engl J Med"},{"key":"3268_CR56","doi-asserted-by":"publisher","unstructured":"Liang, Q., Zhu, Q.Y., Fang, X.Y., Wei, J., Xu, Y.E., Zuo, Y., Bu, G.L., Xie, C., Shan, S., Sun, C., et al. (2026). A potent human neutralizing antibody targeting the receptor-binding site in the glycoprotein gp350 of Epstein-Barr virus. Sci China Life Sci doi: https:\/\/doi.org\/10.1007\/s11427-025-3102-7.","DOI":"10.1007\/s11427-025-3102-7"},{"key":"3268_CR57","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin, J.C., Wang, W.Y., Chen, K.Y., Wei, Y.H., Liang, W.M., Jan, J.S., and Jiang, R.S. (2004). Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350, 2461\u20132470.","journal-title":"N Engl J Med"},{"key":"3268_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12885-024-12564-4","volume":"24","author":"S Lin","year":"2024","unstructured":"Lin, S., Zhou, H., Chen, G., Xue, J., Liu, Q., Li, J., Yang, Y., Zhao, Y., Bao, H., Huang, Y., et al. (2024). Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. BMC Cancer 24, 797.","journal-title":"BMC Cancer"},{"key":"3268_CR59","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","volume":"93","author":"LT Liu","year":"2015","unstructured":"Liu, L.T., Tang, L.Q., Chen, Q.Y., Zhang, L., Guo, S.S., Guo, L., Mo, H.Y., Zhao, C., Guo, X., Cao, K.J., et al. (2015). The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 93, 862\u2013869.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3268_CR60","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/aje\/kws404","volume":"177","author":"Z Liu","year":"2013","unstructured":"Liu, Z., Ji, M.F., Huang, Q.H., Fang, F., Liu, Q., Jia, W.H., Guo, X., Xie, S.H., Chen, F., Liu, Y., et al. (2013). Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am J Epidemiol 177, 242\u2013250.","journal-title":"Am J Epidemiol"},{"key":"3268_CR61","first-page":"6878","volume":"60","author":"YM Lo","year":"2000","unstructured":"Lo, Y.M., Chan, A.T., Chan, L.Y., Leung, S.F., Lam, C.W., Huang, D.P., and Johnson, P.J. (2000a). Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60, 6878\u20136881.","journal-title":"Cancer Res"},{"key":"3268_CR62","first-page":"5452","volume":"59","author":"YM Lo","year":"1999","unstructured":"Lo, Y.M., Chan, L.Y., Chan, A.T., Leung, S.F., Lo, K.W., Zhang, J., Lee, J.C., Hjelm, N. M., Johnson, P.J., and Huang, D.P. (1999a). Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59, 5452\u20135455.","journal-title":"Cancer Res"},{"key":"3268_CR63","first-page":"1188","volume":"59","author":"YM Lo","year":"1999","unstructured":"Lo, Y.M., Chan, L.Y., Lo, K.W., Leung, S.F., Zhang, J., Chan, A.T., Lee, J.C., Hjelm, N. M., Johnson, P.J., and Huang, D.P. (1999b). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59, 1188\u20131191.","journal-title":"Cancer Res"},{"key":"3268_CR64","first-page":"2351","volume":"60","author":"YM Lo","year":"2000","unstructured":"Lo, Y.M., Leung, S.F., Chan, L.Y., Chan, A.T., Lo, K.W., Johnson, P.J., and Huang, D.P. (2000b). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60, 2351\u20132355.","journal-title":"Cancer Res"},{"key":"3268_CR65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2000.tb06597.x","volume":"906","author":"YMD Lo","year":"2000","unstructured":"Lo, Y.M.D., Leung, S.F., Chan, L.Y.S., Lo, K.W., Zhang, J., Chan, A.T.C., Lee, J.C.K., Hjelm, N.M., Johnson, P.J., and Huang, D.P. (2000c). Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma: correlation with clinical staging. Ann N Y Acad Sci 906, 99\u2013101.","journal-title":"Ann N Y Acad Sci"},{"key":"3268_CR66","first-page":"256","volume":"63","author":"J Lu","year":"2003","unstructured":"Lu, J., Chua, H.H., Chen, S.Y., Chen, J.Y., and Tsai, C.H. (2003). Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63, 256\u2013262.","journal-title":"Cancer Res"},{"key":"3268_CR67","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv, J., Chen, Y., Zhou, G., Qi, Z., Tan, K.R.L., Wang, H., Lin, L., Chen, F., Zhang, L., Huang, X., et al. (2019). Liquid biopsy tracking during sequential chemoradiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun 10, 3941.","journal-title":"Nat Commun"},{"key":"3268_CR68","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv, J., Wei, Y., Yin, J.H., Chen, Y.P., Zhou, G.Q., Wei, C., Liang, X.Y., Zhang, Y., Zhang, C.J., He, S.W., et al. (2023). The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med 29, 1424\u20131436.","journal-title":"Nat Med"},{"key":"3268_CR69","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12916-022-02463-5","volume":"20","author":"J Lv","year":"2022","unstructured":"Lv, J., Wu, C., Li, J., Chen, F., He, S., He, Q., Zhou, G., Ma, J., Sun, Y., Wei, D., et al. (2022). Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Med 20, 268.","journal-title":"BMC Med"},{"key":"3268_CR70","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv, J., Xu, L.X., Li, Z.X., Lin, L., Wu, C.F., Quan, T.Q., Zhen, Z.C., Li, W.F., Tang, L.L., Mao, Y.P., et al. (2024). Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EPSEASON study. Cancer Cell 42, 1401\u20131414.e4.","journal-title":"Cancer Cell"},{"key":"3268_CR71","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ijrobp.2006.05.064","volume":"66","author":"BBY Ma","year":"2006","unstructured":"Ma, B.B.Y., King, A., Lo, Y.M.D., Yau, Y.Y., Zee, B., Hui, E.P., Leung, S.F., Mo, F., Kam, M.K., Ahuja, A., et al. (2006). Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66, 714\u2013720.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3268_CR72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua, M.J.M., Brown Swigart, L., Ahmed, Z., Sayaman, R.W., Renner, D., Kalashnikova, E., Hirst, G.L., Yau, C., Wolf, D.M., Li, W., et al. (2023). Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell 41, 1091\u20131102.e4.","journal-title":"Cancer Cell"},{"key":"3268_CR73","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/v13122344","volume":"13","author":"T Murata","year":"2021","unstructured":"Murata, T., Sugimoto, A., Inagaki, T., Yanagi, Y., Watanabe, T., Sato, Y., and Kimura, H. (2021). Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation. Viruses 13, 2344.","journal-title":"Viruses"},{"key":"3268_CR74","first-page":"665","volume":"4","author":"A Mutirangura","year":"1998","unstructured":"Mutirangura, A., Pornthanakasem, W., Theamboonlers, A., Sriuranpong, V., Lertsanguansinchi, P., Yenrudi, S., Voravud, N., Supiyaphun, P., and Poovorawan, Y. (1998). Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 4, 665\u2013669.","journal-title":"Clin Cancer Res"},{"key":"3268_CR75","doi-asserted-by":"publisher","first-page":"11767","DOI":"10.1038\/srep11767","volume":"5","author":"Y Narita","year":"2015","unstructured":"Narita, Y., Sugimoto, A., Kawashima, D., Watanabe, T., Kanda, T., Kimura, H., Tsurumi, T., and Murata, T. (2015). A herpesvirus specific motif of Epstein-Barr virus DNA polymerase is required for the efficient lytic genome synthesis. Sci Rep 5, 11767.","journal-title":"Sci Rep"},{"key":"3268_CR76","doi-asserted-by":"publisher","first-page":"e1005195","DOI":"10.1371\/journal.ppat.1005195","volume":"11","author":"DM Nawandar","year":"2015","unstructured":"Nawandar, D.M., Wang, A., Makielski, K., Lee, D., Ma, S., Barlow, E., Reusch, J., Jiang, R., Wille, C.K., Greenspan, D., et al. (2015). Differentiation-dependent KLF4 expression promotes lytic Epstein-Barr virus infection in epithelial cells. PLoS Pathog 11, e1005195.","journal-title":"PLoS Pathog"},{"key":"3268_CR77","doi-asserted-by":"publisher","first-page":"115396","DOI":"10.1016\/j.ejca.2025.115396","volume":"220","author":"J Neo","year":"2025","unstructured":"Neo, J., Ong, E.H.W., Zhang, X., Chow, W.M., Wee, J.T.S., Fong, K.W., Soong, Y.L., Tan, T.W.K., Liu, J., Loh, K.S., et al. (2025). Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: analysis of a real-world database. Eur J Cancer 220, 115396.","journal-title":"Eur J Cancer"},{"key":"3268_CR78","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan, Y., Zhang, J.T., Gao, X., Chen, Z.Y., Yan, B., Tan, P.X., Yang, X.R., Gao, W., Gong, Y., Tian, Z., et al. (2023). Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell 41, 1763\u20131773.e4.","journal-title":"Cancer Cell"},{"key":"3268_CR79","doi-asserted-by":"publisher","first-page":"689593","DOI":"10.3389\/fonc.2021.689593","volume":"11","author":"H Peng","year":"2021","unstructured":"Peng, H., Chen, B., Wang, X., Mo, Y.X., and Han, F. (2021). Prognostic value of regression rate of plasma EBV DNA after induction chemotherapy for stage II-IVA nasopharyngeal carcinoma. Front Oncol 11, 689593.","journal-title":"Front Oncol"},{"key":"3268_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00405-019-05699-9","volume":"277","author":"H Qu","year":"2020","unstructured":"Qu, H., Huang, Y., Zhao, S., Zhou, Y., and Lv, W. (2020). Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol 277, 9\u201318.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"3268_CR81","doi-asserted-by":"publisher","first-page":"e1004322","DOI":"10.1371\/journal.ppat.1004322","volume":"10","author":"LL Quinn","year":"2014","unstructured":"Quinn, L.L., Zuo, J., Abbott, R.J.M., Shannon-Lowe, C., Tierney, R.J., Hislop, A.D., and Rowe, M. (2014). Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. PLoS Pathog 10, e1004322.","journal-title":"PLoS Pathog"},{"key":"3268_CR82","doi-asserted-by":"publisher","first-page":"12494","DOI":"10.1128\/JVI.01705-12","volume":"86","author":"S Ramasubramanyan","year":"2012","unstructured":"Ramasubramanyan, S., Kanhere, A., Osborn, K., Flower, K., Jenner, R.G., and Sinclair, A.J. (2012). Genome-wide analyses of zta binding to the Epstein-Barr virus genome reveals interactions in both early and late lytic cycles and an epigenetic switch leading to an altered binding profile. J Virol 86, 12494\u201312502.","journal-title":"J Virol"},{"key":"3268_CR83","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1373\/clinchem.2016.262337","volume":"63","author":"F Riva","year":"2017","unstructured":"Riva, F., Bidard, F.C., Houy, A., Saliou, A., Madic, J., Rampanou, A., Hego, C., Milder, M., Cottu, P., Sablin, M.P., et al. (2017). Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem 63, 691\u2013699.","journal-title":"Clin Chem"},{"key":"3268_CR84","first-page":"101475","volume":"55","author":"NF Saba","year":"2025","unstructured":"Saba, N.F., and Ma, B.B.Y. (2025). The potential of real-time dynamic disease monitoring with circulating tumor DNA: important lessons from Epstein-Barr virus-related nasopharyngeal carcinoma. Lancet Reg Health West Pac 55, 101475.","journal-title":"Lancet Reg Health West Pac"},{"key":"3268_CR85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virusres.2013.01.016","volume":"174","author":"E Sakka","year":"2013","unstructured":"Sakka, E., Hausen, A., Houali, K., Liu, H., Fiorini, S., and Ooka, T. (2013). Cellular localization of BARF1 oncoprotein and its cell stimulating activity in human epithelial cell. Virus Res 174, 8\u201317.","journal-title":"Virus Res"},{"key":"3268_CR86","doi-asserted-by":"publisher","first-page":"e1000530","DOI":"10.1371\/journal.ppat.1000530","volume":"5","author":"Y Sato","year":"2009","unstructured":"Sato, Y., Kamura, T., Shirata, N., Murata, T., Kudoh, A., Iwahori, S., Nakayama, S., Isomura, H., Nishiyama, Y., Tsurumi, T., et al. (2009). Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog 5, e1000530.","journal-title":"PLoS Pathog"},{"key":"3268_CR87","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2023012183","volume":"8","author":"S Sharma","year":"2024","unstructured":"Sharma, S., Mehta, N.U., Sauer, T., Rollins, L.A., Dittmer, D.P., and Rooney, C.M. (2024). Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv 8, 3360\u20133371.","journal-title":"Blood Adv"},{"key":"3268_CR88","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/jvi.29.2.657-665.1979","volume":"29","author":"JE Shaw","year":"1979","unstructured":"Shaw, J.E., Levinger, L.F., and CarterJr, C.W. (1979). Nucleosomal structure of Epstein-Barr virus DNA in transformed cell lines. J Virol 29, 657\u2013665.","journal-title":"J Virol"},{"key":"3268_CR89","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fgene.2013.00161","volume":"4","author":"AJ Sinclair","year":"2013","unstructured":"Sinclair, A.J. (2013). Epigenetic control of Epstein-Barr virus transcription\u2014relevance to viral life cycle? Front Genet 4, 161.","journal-title":"Front Genet"},{"key":"3268_CR90","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1245\/s10434-014-3621-x","volume":"21","author":"W Sohn","year":"2014","unstructured":"Sohn, W., Paik, Y.H., Kim, J.M., Kwon, C.H., Joh, J.W., Cho, J.Y., Gwak, G.Y., Choi, M. S., Lee, J.H., Koh, K.C., et al. (2014). HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol 21, 2429\u20132435.","journal-title":"Ann Surg Oncol"},{"key":"3268_CR91","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/microorganisms10050896","volume":"10","author":"A Sugimoto","year":"2022","unstructured":"Sugimoto, A. (2022). Replication compartments\u2014the great survival strategy for Epstein-Barr virus lytic replication. Microorganisms 10, 896.","journal-title":"Microorganisms"},{"key":"3268_CR92","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.semcancer.2011.12.007","volume":"22","author":"K Takada","year":"2012","unstructured":"Takada, K. (2012). Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Semin Cancer Biol 22, 162\u2013165.","journal-title":"Semin Cancer Biol"},{"key":"3268_CR93","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","volume":"41","author":"L Tang","year":"2021","unstructured":"Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021). The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun 41, 1195\u20131227.","journal-title":"Cancer Commun"},{"key":"3268_CR94","first-page":"3254","volume":"9","author":"EW To","year":"2003","unstructured":"To, E.W., Chan, K.C., Leung, S.F., Chan, L.Y., To, K.F., Chan, A.T., Johnson, P.J., and Lo, Y.M. (2003). Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9, 3254\u20133259.","journal-title":"Clin Cancer Res"},{"key":"3268_CR95","doi-asserted-by":"publisher","first-page":"20160270","DOI":"10.1098\/rstb.2016.0270","volume":"372","author":"SW Tsao","year":"2017","unstructured":"Tsao, S.W., Tsang, C.M., and Lo, K.W. (2017). Epstein-Barr virus infection and nasopharyngeal carcinoma. Phil Trans R Soc B 372, 20160270.","journal-title":"Phil Trans R Soc B"},{"key":"3268_CR96","doi-asserted-by":"publisher","first-page":"e1010045","DOI":"10.1371\/journal.ppat.1010045","volume":"17","author":"N Van Sciver","year":"2021","unstructured":"Van Sciver, N., Ohashi, M., Nawandar, D.M., Pauly, N.P., Lee, D., Makielski, K.R., Bristol, J.A., Tsao, S.W., Lambert, P.F., Johannsen, E.C., et al. (2021). \u0394Np63\u03b1 promotes Epstein-Barr virus latency in undifferentiated epithelial cells. PLoS Pathog 17, e1010045.","journal-title":"PLoS Pathog"},{"key":"3268_CR97","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11427-023-2737-2","volume":"68","author":"D Wang","year":"2025","unstructured":"Wang, D., Zuo, S., Ge, J., Qu, H., Wu, J., Yi, N., Shi, L., Wang, Y., Mo, Y., Fan, C., et al. (2025). circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1\/Hippo signaling pathway. Sci China Life Sci 68, 689\u2013705.","journal-title":"Sci China Life Sci"},{"key":"3268_CR98","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1158\/1078-0432.CCR-09-2796","volume":"16","author":"WY Wang","year":"2010","unstructured":"Wang, W.Y., Twu, C.W., Chen, H.H., Jan, J.S., Jiang, R.S., Chao, J.Y.C., Liang, K.L., Chen, K.W., Wu, C.T., and Lin, J.C. (2010). Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic\/recurrent nasopharyngeal carcinoma. Clin Cancer Res 16, 1016\u20131024.","journal-title":"Clin Cancer Res"},{"key":"3268_CR99","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/cncr.27853","volume":"119","author":"W Wang","year":"2013","unstructured":"Wang, W., Twu, C., Chen, H., Jiang, R., Wu, C., Liang, K., Shih, Y., Chen, C., Lin, P., Liu, Y., et al. (2013). Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer 119, 963\u2013970.","journal-title":"Cancer"},{"key":"3268_CR100","doi-asserted-by":"publisher","first-page":"e1003741","DOI":"10.1371\/journal.pmed.1003741","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Yang, L., Bao, H., Fan, X., Xia, F., Wan, J., Shen, L., Guan, Y., Bao, H., Wu, X., et al. (2021). Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study. PLoS Med 18, e1003741.","journal-title":"PLoS Med"},{"key":"3268_CR101","doi-asserted-by":"publisher","first-page":"1505191","DOI":"10.3389\/fmicb.2024.1505191","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Yu, J., and Pei, Y. (2024). Identifying the key regulators orchestrating Epstein-Barr virus reactivation. Front Microbiol 15, 1505191.","journal-title":"Front Microbiol"},{"key":"3268_CR102","first-page":"5781","volume":"60","author":"EM Westphal","year":"2000","unstructured":"Westphal, E.M., Blackstock, W., Feng, W., Israel, B., and Kenney, S.C. (2000). Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 60, 5781\u20135788.","journal-title":"Cancer Res"},{"key":"3268_CR103","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.coviro.2013.03.005","volume":"3","author":"A Woellmer","year":"2013","unstructured":"Woellmer, A., and Hammerschmidt, W. (2013). Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. Curr Opin Virol 3, 260\u2013265.","journal-title":"Curr Opin Virol"},{"key":"3268_CR104","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/nar\/gkp1169","volume":"38","author":"CC Wu","year":"2010","unstructured":"Wu, C.C., Liu, M.T., Chang, Y.T., Fang, C.Y., Chou, S.P., Liao, H.W., Kuo, K.L., Hsu, S. L., Chen, Y.R., Wang, P.W., et al. (2010). Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res 38, 1932\u20131949.","journal-title":"Nucleic Acids Res"},{"key":"3268_CR105","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","volume":"43","author":"C Xu","year":"2025","unstructured":"Xu, C., Zhou, G.Q., Li, W.F., Hu, D.S., Chen, X.Z., Lin, S.J., Jin, F., Huang, X.Q., Peng, G., Huang, J., et al. (2025). Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: a multicenter phase 2 PLATINUM trial. Cancer Cell 43, 925\u2013936.e4.","journal-title":"Cancer Cell"},{"key":"3268_CR106","doi-asserted-by":"publisher","first-page":"e220587","DOI":"10.1001\/jamanetworkopen.2022.0587","volume":"5","author":"JY Xu","year":"2022","unstructured":"Xu, J.Y., Wei, X.L., Ren, C., Zhang, Y., Hu, Y.F., Li, J.Y., Chen, J.L., Wang, Y.Q., Han, F., and Wang, F.H. (2022). Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open 5, e220587.","journal-title":"JAMA Netw Open"},{"key":"3268_CR107","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ccell.2025.04.009","volume":"43","author":"S Zhang","year":"2025","unstructured":"Zhang, S., Zhou, Y., Liu, Z., Wang, Y., Zhou, X., Chen, H., Zhang, X., Chen, Y., Feng, Q., Ye, X., et al. (2025). Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma. Cancer Cell 43, 1423\u20131441.e10.","journal-title":"Cancer Cell"},{"key":"3268_CR108","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11427-024-2766-0","volume":"68","author":"LY Zhong","year":"2025","unstructured":"Zhong, L.Y., Xie, C., Zhang, L.L., Yang, Y.L., Liu, Y.T., Zhao, G.X., Bu, G.L., Tian, X.S., Jiang, Z.Y., Yuan, B.Y., et al. (2025). Research landmarks on the 60th anniversary of Epstein-Barr virus. Sci China Life Sci 68, 354\u2013380.","journal-title":"Sci China Life Sci"},{"key":"3268_CR109","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1038\/s41467-020-17672-w","volume":"11","author":"GQ Zhou","year":"2020","unstructured":"Zhou, G.Q., Wu, C.F., Deng, B., Gao, T.S., Lv, J.W., Lin, L., Chen, F., Kou, J., Zhang, Z. X., Huang, X.D., et al. (2020). An optimal posttreatment surveillance strategy for cancer survivors based on an individualized risk-based approach. Nat Commun 11, 3872.","journal-title":"Nat Commun"},{"key":"3268_CR110","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1078-0432.CCR-20-2299","volume":"27","author":"J Zhou","year":"2021","unstructured":"Zhou, J., Wang, C., Lin, G., Xiao, Y., Jia, W., Xiao, G., Liu, Q., Wu, B., Wu, A., Qiu, H., et al. (2021). Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study. Clin Cancer Res 27, 301\u2013310.","journal-title":"Clin Cancer Res"},{"key":"3268_CR111","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1078-0432.CCR-21-3231","volume":"28","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q., Gampenrieder, S.P., Frantal, S., Rinnerthaler, G., Singer, C.F., Egle, D., Pfeiler, G., Bartsch, R., Wette, V., Pichler, A., et al. (2022). Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response. Clin Cancer Res 28, 697\u2013707.","journal-title":"Clin Cancer Res"},{"key":"3268_CR112","doi-asserted-by":"publisher","first-page":"e1000255","DOI":"10.1371\/journal.ppat.1000255","volume":"5","author":"J Zuo","year":"2009","unstructured":"Zuo, J., Currin, A., Griffin, B.D., Shannon-Lowe, C., Thomas, W.A., Ressing, M.E., Wiertz, E.J.H.J., and Rowe, M. (2009). The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5, e1000255.","journal-title":"PLoS Pathog"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3268-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:33:37Z","timestamp":1792085617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3268-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":112,"alternative-id":["3268"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3268-1","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}